Results 111 to 120 of about 57,284 (206)

Mineralocorticoid receptor antagonists promote renal immunosenescence. [PDF]

Int Urol Nephrol
Wang QR, Yang Y.
europepmc   +1 more source

Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice. [PDF]

Clin Sci (Lond)
Tesch GH, Ozols E, Morgan J, Young MJ, Nikolic-Paterson DJ.   +4 more
europepmc   +1 more source

Intercellular communication from myotubes to fibroblasts is differentially impacted by mineralocorticoid receptor signaling and muscular dystrophy. [PDF]

Cell Commun Signal
Krishna S, Gomatam CK, Reddy R, Lowe J, Lepper C, Rafael-Fortney JA.   +5 more
europepmc   +1 more source

Mineralocorticoid Receptors [PDF]

Circulation Research, 2020
openaire   +3 more sources

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists. [PDF]

Rev Cardiovasc Med
Bozkurt B, Januzzi JL, Bansal S.
europepmc   +1 more source

The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice. [PDF]

Cardiovasc Diabetol
Manon MF, Marie PD, Benjamin B, Coralie F, Linghui K, Amhrae ND, Lionel N, Saïda M, Sylvanie R, Anaïs D, Vincent R, Bruno F, Frédéric J, Sheerazed B, Paul M, Antoine OP.   +15 more
europepmc   +1 more source

Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. [PDF]

J Am Heart Assoc
Wu JY, Tseng KJ, Lin YM.
europepmc   +1 more source

A novel mineralocorticoid receptor blocker, CS-3150, improves insulin resistance and reduces inflammation in db/db mice. [PDF]

Korean J Physiol Pharmacol
Bavuu O, Fukuda D, Munkhjargal U, Ganbaatar B, Hara T, Yagi S, Soeki T, Sata M.   +7 more
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. [PDF]

BMC Cardiovasc Disord
Wu J, Pei Y, Wu J, Huang Y.
europepmc   +1 more source

Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial. [PDF]

BMJ Open
Merabtine A, Leung AA, Kline GA, Dubrofsky L, Hundemer GL, Goupil R.   +5 more
europepmc   +1 more source